Your browser doesn't support javascript.
loading
Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials.
Kvien, Tore K; Conaghan, Philip G; Gossec, Laure; Strand, Vibeke; Østergaard, Mikkel; Poddubnyy, Denis; Williams, Nicole; Porter, Brian; Shete, Abhijit; Gilloteau, Isabelle; Deodhar, Atul.
Afiliação
  • Kvien TK; Diakonhjemmet Hospital and University of Oslo, Oslo, Norway.
  • Conaghan PG; University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK.
  • Gossec L; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique and Pitié Salpêtrière Hospital, APHP, Paris, France.
  • Strand V; Stanford University School of Medicine, Palo Alto, California.
  • Østergaard M; Rigshospitalet, Glostrup, and University of Copenhagen, Copenhagen, Denmark.
  • Poddubnyy D; Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany.
  • Williams N; RTI Health Solutions, Durham, North Carolina.
  • Porter B; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • Shete A; Novartis Pharma AG, Basel, Switzerland.
  • Gilloteau I; Novartis Pharma AG, Basel, Switzerland.
  • Deodhar A; Oregon Health and Science University, Portland.
Arthritis Care Res (Hoboken) ; 74(5): 759-767, 2022 05.
Article em En | MEDLINE | ID: mdl-33227175

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Espondilite Anquilosante / Fadiga / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Espondilite Anquilosante / Fadiga / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article